We adopt an environmental, social, governance (ESG) approach to our sustainability and sustainability reporting efforts. We focus on each of these three areas separately. We minimize our environmental footprint; we work on Human Resources and social issues with employees and in a broader societal context; and address governance issues by ensuring that we operate fairly, transparently, and to high ethical standards.
To achieve this comprehensive ESG approach, we have drawn up a set of policies. A key component of this process was – and remains – engaging with stakeholders to ensure that we address relevant issues. We aim to align with key metrics of global sustainability frameworks, and support the United Nations Global Compact principles.
Oncopeptides also supports the UN’s 2030 Agenda and Sustainable Development Goals (SDGs) and actively contribute to two of the SDGs in which we think we have the most impact and can help drive positive change. SDG 3: Good health and well-being - Ensure healthy lives and promote well-being for all at all ages, and SDG 13: Climate action - Take urgent action to combat climate change and its impacts.
In 2021, we plan to conduct a materiality analysis to identify areas that are most material to the company. This will help focus our efforts on sustainability and lead to more formal treatment of sustainability. We are conducting ongoing dialogs with stakeholders that will help shape our sustainability work and ESG focus. By incorporating stakeholders’ views and expectations we can maintain our awareness and continuous development by addressing relevant issues and how to prioritize and integrate them into our ESG work as we look to further formalize our approach to sustainability.